Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matija Tomsic

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Metabolomics : Official Journal of the Metabolomic Society|June 23, 2016
Metabolic fingerprints of human primary endothelial and fibroblast cellsPolona Žigon, Katjuša Mrak-Poljšak, Katja Lakota, et al.
Orbit (Amsterdam, Netherlands)|December 20, 2024
Janus kinase inhibitors and their use in non-infectious orbital inflammatory disorders: new treatment possibilities? A case seriesNina Vidic Krhlikar, Matija Tomsic, Polona Jaki Mekjavic, et al.
Plos One|January 29, 2015
Serum amyloid A is a marker for pulmonary involvement in systemic sclerosisKatja Lakota, Mary Carns, Sofia Podlusky, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 8, 2009
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritisPetra Bohanec Grabar, Iztok Grabnar, Blaz Rozman, et al.
Autoimmunity|August 13, 2010
Could antibodies against serum amyloid A function as physiological regulators in humans?Katja Lakota, Gerhard G Thallinger, Sasa Cucnik, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|April 22, 2009
Solubilization of poly{1,4-phenylene-[9,9-bis(4-phenoxy-butylsulfonate)]fluorene-2,7-diyl} in water by nonionic amphiphilesHugh D Burrows, María J Tapia, Sofia M Fonseca, et al.
Annals of the Rheumatic Diseases|October 6, 2011
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaborationKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Annals of the Rheumatic Diseases|May 17, 2011
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|April 2, 2011
Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countriesEwa Orlewska, Ioan Ancuta, Branimir Anic, et al.
Arthritis Research & Therapy|February 18, 2016
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Metabolomics : Official Journal of the Metabolomic Society|June 23, 2016
Metabolic fingerprints of human primary endothelial and fibroblast cellsPolona Žigon, Katjuša Mrak-Poljšak, Katja Lakota, et al.
Orbit (Amsterdam, Netherlands)|December 20, 2024
Janus kinase inhibitors and their use in non-infectious orbital inflammatory disorders: new treatment possibilities? A case seriesNina Vidic Krhlikar, Matija Tomsic, Polona Jaki Mekjavic, et al.
Plos One|January 29, 2015
Serum amyloid A is a marker for pulmonary involvement in systemic sclerosisKatja Lakota, Mary Carns, Sofia Podlusky, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 8, 2009
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritisPetra Bohanec Grabar, Iztok Grabnar, Blaz Rozman, et al.
Autoimmunity|August 13, 2010
Could antibodies against serum amyloid A function as physiological regulators in humans?Katja Lakota, Gerhard G Thallinger, Sasa Cucnik, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|April 22, 2009
Solubilization of poly{1,4-phenylene-[9,9-bis(4-phenoxy-butylsulfonate)]fluorene-2,7-diyl} in water by nonionic amphiphilesHugh D Burrows, María J Tapia, Sofia M Fonseca, et al.
Annals of the Rheumatic Diseases|October 6, 2011
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaborationKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Annals of the Rheumatic Diseases|May 17, 2011
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|April 2, 2011
Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countriesEwa Orlewska, Ioan Ancuta, Branimir Anic, et al.
Arthritis Research & Therapy|February 18, 2016
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Pageof 5